Table 1 Patient characteristics and outcome
From: Differentiating midazolam over-sedation from neurological damage in the intensive care unit
Characteristics | Midazolam-positive group (n = 13) | Midazolam-negative group (n = 13) | Statistics |
|---|---|---|---|
Admission diagnosis | |||
Cardiothoracic surgery | 8 | 6 | |
Severe sepsis | 0 | 4 | |
Cardiorespiratory arrest | 2 | 1 | |
General surgery | 2 | 0 | |
Pancreatitis | 1 | 0 | |
Acute asthma | 0 | 1 | |
Perforated duodenal ulcer | 0 | 1 | |
APACHE II score (day 1; mean ± standard deviation) | 19.1 ± 6.6 | 19.4 ± 7.1 | |
Renal Impairment (serum creatinine >130 μmol/l or receiving renal replacement therapy) | 5 | 4 | |
Neurological function intact | 10 | 3 | P < 0.002a |
Neurological damage | 3 | 10 | P < 0.002a |
All-cause mortality | 4 (31%) | 8 (62%) | |
Median midazolam dose mg/hour (range; 24 hours before cessation) | 4 (2–20) | 3.5 (2–15) | NSb |
Median time (range) from midazolam cessation (hrs) | 66 (36–120) | 68 (36–146) | NSb |